Yarrow Bioscience, Inc.: AMERIPRISE FINANCIAL INC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Ameriprise Financial Inc. disclosed a stake of more than 5% in Yarrow Bioscience, Inc. via a Schedule 13G filing with the SEC (accession 0001193125-26-462440). The passive-investor disclosure signals a significant institutional position in the bioscience company. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G/13D amendments and any subsequent changes in Ameriprise's holdings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Yarrow Bioscience, Inc., Ameriprise Financial Inc.